Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

[Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma].

Author information

Affiliations

  • 1. Klinik und Poliklinik für Urologie und Kinderurologie, Universitätsklinikum Bonn (UKB), Bonn, Deutschland.
      Authors
    • Klümper N 1
    (1 author)
  • 2. Institut für Pathologie, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Deutschland.
      Authors
    • Eckstein M 2
    (1 author)
  • 3. Klinik für Urologie und Kinderurologie, Klinikum Bayreuth GmbH, Bayreuth, Deutschland.
      Authors
    • Kunath F 3
    (1 author)
  • 4. Department für Urologie, Medizinische Universität Innsbruck, Innsbruck, Österreich.
      Authors
    • Heidegger I 4
    (1 author)
  • 5. Ressort Forschungsförderung, Deutsche Gesellschaft für Urologie e. V., Düsseldorf, Deutschland.
      Authors
    • Becker C 5
    (1 author)
    • Show all (6)

ORCIDs linked to this article

Urologie (Heidelberg, Germany), 01 Sep 2023, 62(11):1193-1199Language:ger
https://doi.org/10.1007/s00120-023-02175-5 PMID: 37658236 

Review

Abstract 

This compact review article highlights the background and importance of nectins in cancer therapy, focusing specifically on the antibody-drug conjugate enfortumab vedotin (EV) as a targeted treatment option for metastatic urothelial carcinoma. The evolving understanding of nectin-4 expression and its impact on EV therapy underscores the need for personalized approaches to ensure optimal patient outcomes. Further investigation into biomarker-guided therapies and prospective clinical trials are critical to refining patient selection and treatment strategies.

Full text links 

Read article at publisher's site: https://doi.org/10.1007/s00120-023-02175-5

References 

Articles referenced by this article (27)

Show 10 more references (10 of 27)

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.